China's R&D Outsourcing Market Reaches $315 Million, Expected To Maintain High Growth Through 2016
This article was originally published in The Pink Sheet Daily
Executive Summary
IPO for ShangPharma, China's second-largest CRO after the leading WuXi PharmaTech, debuted Oct. 19.